Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 51, 4395-4401, August 15, 1991]
© 1991 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fleck, J. F.
Right arrow Articles by Hirsch, K. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fleck, J. F.
Right arrow Articles by Hirsch, K. S.

Binding of Insulin-like Growth Factors to Tera-2 Human Embryonal Carcinoma Cells during Differentiation1

James F. Fleck, George W. Sledge, Jr., Sue V. Benenati, Charles A. Frolik, Bruce J. Roth and Kenneth S. Hirsch2

Department of Medicine, Indiana University School of Medicine, and Richard L. Roudebush VA Medical Center and the Walther Oncology Center, Indianapolis 46202 [J. F. F., S. V. B., B. J. R., G. W. S.], and Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285 [K. S. H., C. A. F.]

Differentiation of Tera-2 human embryonal carcinoma cells by exposure to 2.1 mM {alpha}-difluoromethylornithine resulted in changes in morphology, a decrease in growth rate, and changes in the expression of SSEA-1 differentiation antigen. While the binding of 125I-insulin-like growth factor I (IGF-I) remained relatively constant during differentiation, binding of 125I-IGF-II increased 2-3-fold. Further, the binding of IGF-II was 87 times greater than IGF-I in both undifferentiated and differentiated cells. Undifferentiated Tera-2 cells exhibited a single class of binding sites for both IGF-I (KD = 1.2 nM, 7.0 x 103 sites/cell) and IGF-II (KD = 8.3 nM, 3.4 x 105 sites/cell). Following differentiation, IGF-I continued to bind to a single class of binding sites (KD 1.0 nM, 6.7 x 103 sites/cell) whereas IGF-II bound to both high-affinity sites (KDH 0.3 nM, 2.2 x 105 sites/cell) and low-affinity sites (KDL 15.1 nM, 1.6 x 107 sites/cell). The binding of iodinated IGF-II was blocked by unlabeled IGF-II but not IGF-I. In contrast, 125I-IGF-I binding was prevented by either IGF-I or IGF-II. Affinity cross-linking experiments demonstrated the presence of both type I and type II IGF receptors along with a number of IGF binding proteins. IGF-I failed to stimulate the incorporation of [3H]thymidine in both undifferentiated and differentiated cells. Although IGF-II caused a significant increase in [3H]thymidine incorporation in both undifferentiated and differentiated Tera-2 cells, the magnitude of the response and the sensitivity of the cells to IGF-II stimulation was diminished following differentiation. The observed changes in IGF-II binding, which occur in conjunction with cellular differentiation, may be an important feature of the expression of the differentiated phenotype by human germ cell tumors.

1 J. F. F. is supported by Grant 203422/86-CL of the National Research Council of Brazil (CNPq). G. W. S. and B. J. R. are supported by a VA Merit Review Award and a grant from the Walther Cancer Foundation.

2 To whom requests for reprints should be addressed, at Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285.

Received 5/ 7/90. Accepted 6/10/91.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1991 by the American Association for Cancer Research.